#United States #New York #Wolf Haldenstein #Sarepta Therapeutics #ELEVIDYS

Investor Alert: Class Action Lawsuit Filed Against Sarepta Therapeutics

On July 7, 2025, Wolf Haldenstein Adler Freeman & Herz LLP announced that they have filed a class action lawsuit in the Southern District of New York on behalf of investors who acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023, and June 24, 2025. This action is prompted by allegations that Sarepta made false and misleading statements concerning its gene therapy product, ELEVIDYS, which was developed for treating Duchenne muscular dystrophy (DMD).

Allegations Against Sarepta

The complaint outlines several serious accusations against Sarepta, primarily focusing on the safety and efficacy of ELEVIDYS. Investors allege that the company:

• - Misrepresented the safety profile of ELEVIDYS despite existing serious risks associated with the treatment.
• - Failed to detect or disclose critical adverse events that occurred during clinical trials.
• - Withheld important information which resulted in halted dosing protocols, an increase in regulatory scrutiny, and suspension of shipments.
• - Lacked a reasonable basis for their positive statements regarding the product’s safety and broader applicability.

During the specific Class Period, Sarepta faced significant incidents that negatively impacted its stock value. On March 18, 2025, the firm disclosed the death of a patient receiving ELEVIDYS, leading to a 27.44% drop in stock price. This trend continued as further disclosures regarding clinical trials prompted additional declines: a 7.13% drop on April 4, after the company halted certain studies following a safety review called by European regulators, and a 42.12% decline on June 15, 2025, when another patient death was announced due to acute liver failure.

Moreover, on June 24, 2025, the FDA issued a safety communication concerning the deaths associated with the treatment, causing the shares to decline by another 8.01%.

Investors' Rights and Next Steps

The law firm representing the investors urges anyone who purchased Sarepta securities during this tumultuous period and experienced financial losses to come forward. The deadline for requesting the court to appoint them as the lead plaintiff is August 25, 2025.

Why Choose Wolf Haldenstein?

Founded in 1888, Wolf Haldenstein prides itself on over 125 years of experience in protecting the rights of investors affected by securities litigation. The attorneys at Wolf Haldenstein are committed to achieving justice for those harmed by misleading company statements.

Individuals with information or those who have suffered losses related to Sarepta are encouraged to contact Wolf Haldenstein for assistance. The firm is poised to vigorously pursue compensation for affected investors who have faced financial damages due to the alleged fraudulent conduct of Sarepta Therapeutics.

For more information, parties can reach out via phone at (800) 575-0735 or email Gregory Stone at [email protected]

This lawsuit marks a critical juncture for investors of Sarepta Therapeutics as they seek legal remedies for their losses during a tumultuous trading period. With the eyes of regulatory bodies on Sarepta's operations, the outcome of this lawsuit may also have far-reaching implications for the biopharmaceutical industry.

• ---